Docoh
Loading...
Sign up Log in

QGEN Qiagen

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Company profile

Ticker
QGEN
Exchange
NYSE
Website
www.qiagen.com/
CEO
Thierry Bernard
Employees
Incorporated
Netherlands
Location
Netherlands
Fiscal year end
Dec 31
Sector
Manufacturing > Biological Product (except Diagnostic) Manufacturing
Industry (SIC)
Biological Products, (No Diagnostic Substances)
AMGEN • Gilead Sciences • Biogen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Seagen • Exelixis ...
Former names
QIAGEN NV
SEC CIK
0001015820
Corporate docs

QGEN stock data

(
)

News

Pro users get this 30m faster
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
13 May 21
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Qiagen Q1 Earnings Tops Estimates As Growth In Non-COVID-19 Products Boost Revenues
4 May 21
Recap: Qiagen Q1 Earnings
3 May 21
Shares of Qiagen (NYSE:QGEN) quite in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 94.12% year over year to $0.66, which beat the estimate of $0.63.
Earnings Scheduled For May 3, 2021
3 May 21
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
1 May 21

Press releases

Pro users get this 30m faster
QIAGEN Announces Creation of Scientific Advisory Board and Agenda for Annual General Meeting in June 2021
17 May 21
New Board to consult Managing Board and Supervisory Board on scientific developments to ensure QIAGEN remains at the cutting edge in the Life Sciences and Molecular Diagnostics A Supervisory Board committee is
QIAGEN Receives U.S. FDA Emergency Use Authorization for Fast and Easy-to-Use Digital Test to Detect SARS-CoV-2 Coronavirus Antibodies
12 May 21
U.S. authorization gives healthcare professionals access to portable rapid testing device that can monitor immune status in relation to COVID-19 Test based on QIAGEN partner Ellume's proprietary eHub technology and
QIAGEN NV to Host Earnings Call
4 May 21
NEW YORK, NY / ACCESSWIRE / May 4, 2021 / QIAGEN NV (NYSE:QGEN) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 4, 2021 at 9:00 AM Eastern Time.To listen to the event
QIAGEN Exceeds Outlook in First Quarter 2021 Results, Reaffirms Sales Growth and Profitability Outlook for Full-Year 2021
3 May 21
QIAGEN Announces EZ2 Connect Instrument Line for Automated Sample Processing in Research, Forensics and Diagnostics
29 Apr 21

Calendar

4 Mar 21
18 May 21
31 Dec 21

Financial summary

Financial statements Chart QGEN financial data
Quarter (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Qiagen earnings reports.

Institutional ownership Q4 2020

QGEN institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

53.2% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 265 246 +7.7%
Opened positions 61 52 +17.3%
Closed positions 42 77 -45.5%
Increased positions 111 75 +48.0%
Reduced positions 58 83 -30.1%
13F shares
 Current Prev Q Change
Total value 7.7B 7.25B +6.2%
Total shares 121.3M 99.02M +22.5%
Total puts 500.92K 522.5K -4.1%
Total calls 2.32M 804.2K +188.2%
Total put/call ratio 0.2 0.6 -66.7%
Largest owners
 Shares Value Change
Davidson Kempner Capital Management 16.5M $855.8M -9.7%
Massachusetts Financial Services 11.78M $622.73M NEW
Vanguard 7.44M $393.27M +0.3%
FIL 5.9M $304.29M +35.4%
BLK Blackrock 4.7M $248.26M +2.5%
Millennium Management 4.28M $226.13M -6.1%
Wellington Management 4.21M $219.04M +17.0%
DB Deutsche Bank AG - Registered Shares 4.19M $221.65M +22.6%
Norges Bank 4.02M $208.21M NEW
Amundi Pioneer Asset Management 3.44M $181.9M +12.0%
Largest transactions
 Shares Bought/sold Change
Massachusetts Financial Services 11.78M +11.78M NEW
Norges Bank 4.02M +4.02M NEW
Farallon Capital Management 3.26M +3.26M NEW
C Citigroup 2.76M +1.83M +197.9%
CS Credit Suisse 896.22K -1.78M -66.5%
Davidson Kempner Capital Management 16.5M -1.78M -9.7%
FIL 5.9M +1.54M +35.4%
IVZ Invesco 2.48M +1.53M +162.4%
Premier Fund Managers 1.11M +1.11M NEW
ATAC Neuberger Berman 1.08M +1.06M +5865.9%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Guided Therapeutics • Luminex • Biocept • Exact Sciences • Rosetta Genomics • Veracyte • Nanostring • GenMark Diagnostics • Great Basin Scientific • Co-Diagnostics
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Alliance, anchored, antibody, antigen, ArcherDX, art, attrition, Augsburg, AWE, bad, bargaining, Bearer, Besluit, blended, bulk, career, carryforward, cart, CFO, Champion, childcare, choice, conservation, COVID, dashboard, Decree, delisting, driven, easier, easily, eHub, eighty, EPA, epidemiological, Epitect, EPS, Ernst, ESG, EUA, EUDAMED, exciting, fashion, FDCA, fear, foster, freedom, Haag, Handelsunion, harassment, HITECH, hour, Huttopia, instelling, intimidation, intranet, Invitae, IVCT, Kiel, leaving, lifted, Lonza, MedTech, MHRA, mix, mobilized, narrow, ninety, nondeductibility, nontaxable, Northern, noteholder, NVTA, OncoCyte, openly, OSCE, outperform, pandemic, passion, QIAprep, QIAreach, QIAstat, Quebec, ran, Recovery, remarkable, remediate, renovate, reorder, reprisal, Reproductive, retaliation, revoked, reward, Rheinland, saliva, Scorpion, Scotland, Seal, Secretary, signaled, Simplification, SRD, stay, steep, strictly, strive, struck, Subtitle, therewith, Thyssen, TMO, Toralf, turnover, UK, UKCA, unaudited, vaccine, Verifying, Voith, voluntary, widest, Young
Removed: AB, Acino, Acknowledgement, addressing, aim, Alere, alienation, antibiotic, antiviral, applicant, approvable, arithmetic, Astra, AstraZeneca, Avista, Baker, BIOBASE, biopsy, Biovitrum, BONESUPPORT, breast, bridging, buyback, Canada, capitalization, careHPV, Carolina, Cary, centrifugation, certificate, cesium, check, checked, chloride, CLC, clinically, Coloplast, compound, connect, consistently, coupled, Danisco, debit, density, denying, detecting, diagnosing, DiaSorin, differentiating, digene, divestiture, Draco, EGFR, EGM, embrace, encryption, endorsement, Facsimile, Fax, fight, fighting, filer, focusing, foot, freeing, front, gastrointestinal, GeneRead, GeneReader, Gottlieb, gradient, grew, guiding, head, immunocompromised, immunosuppressive, infection, influenza, Institutet, Interpreta, interpreting, Karolinska, letter, LTBI, Lundbeck, lung, matured, McKenzie, mine, modern, module, momentum, multimodal, multinational, Neuroscience, North, Nycomed, operative, organizational, Orphan, phenol, PHI, play, polymerase, precipitation, precise, preclinical, PRIMECAP, profound, proper, purify, purity, QIAcube, qPCR, QSR, qualitative, question, reaction, returned, satisfaction, Scandinavian, Schatz, Scott, screen, seasoned, shell, simpler, skin, Sobi, solid, SP, standalone, Statue, sterling, stipulated, substance, supplied, surface, surpassed, sustainably, Suzhou, Sweden, Swedish, Switzerland, targeting, TB, Tel, Timetable, transferee, translating, transmit, transplant, transplantation, Trump, tuberculin, unchanged, underway, Unresolved, weaker, widespread, withdrawn
From filing 20-F 2020 FY

Financial reports

View all
20-F
2020 FY
Annual report (foreign)
4 Mar 21
20-F
2019 FY
Annual report (foreign)
1 Mar 20
20-F
2018 FY
Annual report (foreign)
5 Mar 19
20-F
2017 FY
Annual report (foreign)
5 Mar 18
20-F
2016 FY
Annual report (foreign)
5 Mar 17
20-F
2015 FY
Annual report (foreign)
28 Feb 16
20-F
2014 FY
Annual report (foreign)
1 Mar 15
20-F
2013 FY
Annual report (foreign)
2 Mar 14
20-F
2012 FY
Annual report (foreign)
3 Mar 13
20-F
2011 FY
Annual report (foreign)
26 Mar 12

Current reports

View all
6-K
Current report (foreign)
4 May 21
6-K
Current report (foreign)
4 May 21
6-K
Current report (foreign)
24 Feb 21
6-K
Current report (foreign)
9 Feb 21
6-K
Current report (foreign)
8 Jan 21
6-K
Current report (foreign)
18 Dec 20
6-K
Current report (foreign)
17 Dec 20
6-K
Current report (foreign)
10 Dec 20
6-K
Current report (foreign)
8 Dec 20
6-K
Current report (foreign)
12 Nov 20

Registration and prospectus

View all
SC 14D9/A
Tender offer solicitation (amended)
13 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
13 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
11 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
10 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
7 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
6 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
5 Aug 20
SC 14D9/A
Tender offer solicitation (amended)
4 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
4 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
3 Aug 20

Proxies

No filings

Other

View all
SD
Conflict minerals disclosure
26 Mar 21
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
4 Mar 21
SD
Conflict minerals disclosure
29 Mar 20
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
1 Mar 20
UPLOAD
Letter from SEC
1 Oct 19
CORRESP
Correspondence with SEC
24 Sep 19
UPLOAD
Letter from SEC
15 Sep 19
SD
Conflict minerals disclosure
7 May 19
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
5 Mar 19
SD
Conflict minerals disclosure
16 May 18

Ownership

View all
SC 13G/A
QIAGEN / MASSACHUSETTS FINANCIAL SERVICES ownership change
11 Feb 21
SC 13G/A
QIAGEN / WELLINGTON MANAGEMENT ownership change
3 Feb 21
SC 13G/A
QIAGEN / BlackRock ownership change
26 Jan 21
SC 13D/A
QIAGEN / DAVIDSON KEMPNER PARTNERS ownership change
22 Jan 21
SC 13D
QIAGEN / DAVIDSON KEMPNER PARTNERS ownership change
3 Aug 20
SC 13G/A
Qiagen NV
13 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G/A
Beneficial ownership report (amended)
3 Feb 20
SC 13G
Beneficial ownership report
28 Jan 20
SC 13G/A
Beneficial ownership report (amended)
7 Jun 19

Transcripts

2021 Q1
Earnings call transcript
5 May 21
2020 Q4
Earnings call transcript
10 Feb 21

Reddit threads

Pro users get this 30m faster